Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Intrinsic Value
Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. [ Read More ]
The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 32.58 CNY. Compared to the current market price of 22.18 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 32%.
Valuation Backtest
Mayinglong Pharmaceutical Group Co Ltd
Run backtest to discover the historical profit from buying and selling Mayinglong Pharmaceutical Group Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Mayinglong Pharmaceutical Group Co Ltd's business.
What risks and challenges
does Mayinglong Pharmaceutical Group Co Ltd face in the near future?
Summarize the latest earnings report
of Mayinglong Pharmaceutical Group Co Ltd.
Provide P/E
for Mayinglong Pharmaceutical Group Co Ltd and its competitors.
Balance Sheet Decomposition
Mayinglong Pharmaceutical Group Co Ltd
Current Assets | 4.2B |
Cash & Short-Term Investments | 3B |
Receivables | 648.8m |
Other Current Assets | 635.9m |
Non-Current Assets | 871.3m |
Long-Term Investments | 153.2m |
PP&E | 536.4m |
Intangibles | 114.1m |
Other Non-Current Assets | 67.5m |
Current Liabilities | 788.1m |
Accounts Payable | 174.6m |
Accrued Liabilities | 101.7m |
Short-Term Debt | 173.1m |
Other Current Liabilities | 338.7m |
Non-Current Liabilities | 732.2m |
Long-Term Debt | 516.3m |
Other Non-Current Liabilities | 216m |
Earnings Waterfall
Mayinglong Pharmaceutical Group Co Ltd
Revenue
|
3.2B
CNY
|
Cost of Revenue
|
-1.7B
CNY
|
Gross Profit
|
1.5B
CNY
|
Operating Expenses
|
-995.9m
CNY
|
Operating Income
|
456.9m
CNY
|
Other Expenses
|
24.5m
CNY
|
Net Income
|
481.3m
CNY
|
Free Cash Flow Analysis
Mayinglong Pharmaceutical Group Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Mayinglong Pharmaceutical Group Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Mayinglong Pharmaceutical Group Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Mayinglong Pharmaceutical Group Co Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Mayinglong Pharmaceutical Group Co Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Mayinglong Pharmaceutical Group Co Ltd
According to Wall Street analysts, the average 1-year price target for Mayinglong Pharmaceutical Group Co Ltd is 20.45 CNY .
Shareholder Return
Price
Mayinglong Pharmaceutical Group Co Ltd
Average Annual Return | 13.07% |
Standard Deviation of Annual Returns | 26.53% |
Max Drawdown | -44% |
Market Capitalization | 9.6B CNY |
Shares Outstanding | 431 053 891 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei and currently employs 3,208 full-time employees. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 32.58 CNY.
Compared to the current market price of 22.18 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 32%.